PRLD

Prelude Therapeutics Incorporated

PRLD · CIK 1678660 · Annual (10-K) · Last 5 years

Financial Trends

Revenue$7M
20202024
Net Income−$127M
20202024
Operating CF−$103M
20202024
Free Cash Flow−$104M
20202024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Revenue$0.0B————
Cost of Revenue—————
Gross Profit—————
R&D Expense$0.1B$0.1B$0.1B$0.1B$0.0B
SG&A Expense—————
Operating Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B
Net Income$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B
EPS (Basic)$-1.68$-2.02$-2.44——
EPS (Diluted)$-1.68$-2.02$-2.44——

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Total Assets$0.2B$0.3B$0.2B$0.3B$0.2B
Current Assets$0.1B$0.2B$0.2B$0.3B$0.2B
Cash & Equivalents$0.0B$0.0B$0.0B$0.0B$0.2B
Total Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.1B$0.2B$0.2B$0.3B$0.2B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Operating Cash Flow$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B
Investing Cash Flow$0.1B$-0.0B$0.1B$-0.3B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$-0.0B$0.1B$0.0B$0.2B$0.2B
← Companies